Living with Neuroendocrine Tumors
People with neuroendocrine tumors can lead meaningful, active, productive lives. Learn how you can make the most of every day.
The latest in NET News
NETRF Research News August 2024
Welcome to NETRF’s inaugural Research News. This quarterly newsletter features updates on NETRF funded-projects, new clinical trials, and related scientific developments.
Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface
Honoring Leadership: Drs. Shivdasani, Fisher, and Chung Named BOSA Emeritus Members
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
Attend a NET patient conference
Find support groups in your area
Check out patient advocacy groups
2Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;2(1):43-53.